MicroPort® NeuroTech™ Completes NUMEN® Clinical Implantations In Japan

Sendai, Japan, 06 December 2023 — Recently, MicroPort® NeuroTech announced that the NUMEN Coil Embolization System (NUMEN) completed its first batch of clinical implantations in Japan on 10 October. Within three weeks following this announcement, 28 procedures were successfully carried out in 22 Japanese hospitals, receiving positive feedback overall. Adding to this achievement on October 1, NUMEN received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for inclusion in public medical insurance.

The first implantation was jointly performed at Kohnan Hospital in Japan by Dr. Sakata, Dr. Hariu, and Dr. Honma. The patient, a 90-year-old woman, was preoperatively diagnosed with an irregularly shaped ruptured aneurysm in the ICA-PComA segment, measuring approximately 7.8 x 6.5 mm. The surgeons opted for a simple coil embolization approach, using NUMEN for both the embolization filling and finishing stages, with a total of four NUMEN coils implanted (NUMEN MicroFinish 3 x 6 mm, 2.5 x 4 mm, 1.5 x 2 mm, 1.5 x 2 mm). During the procedure, NUMEN was noted for its smooth handling and ease of navigating into residual spaces. With successful and straightforward detachment, NUMEN achieved effective aneurysm occlusion. After the procedure, the medical team highly praised NUMENfor its smooth deliverability, good space seeking capabilities, microcatheter stability during the finishing stages, and its simple, rapid, and reliable detachment process, enabling stable aneurysm embolization.1

To date, both NUMEN and the Numen FRDetachment System have secured approval in China, the EU, the USA, Korea, Brazil, and Japan. They have successfully completed clinical implantation in several countries across Asia-Pacific, North America, and Europe. The recent achievement in Japan marks NUMEN's introduction into the 16th country or region. Its inclusion in Japan’s medical insurance system means NUMEN can benefit more local patients while significantly reducing financial burden. This is a significant step in NeuroTech’s ongoing effort to expand global markets.

MicroPort® NeuroTech continues to enhance its business operations and advance medical R&D. Looking ahead, MicroPort® NeuroTech aims to provide more comprehensive solutions for patients worldwide suffering from cerebral vascular diseases.


As a new generation of electrolytically detachable coils, NUMEN is characterized by its stable basket formation and dense embolization. Its pusher wire features a unique micro-loop design that allows for electrolytic detachment of the coil, potentially reducing surgery time. Made from ultra-fine platinum-tungsten wire and a distinctive three-dimensional structure, NUMEN balances softness with support, significantly reducing pressure on aneurysm walls and ensuring embolization safety. Additionally, NUMEN offers 177 different models across three series, providing physicians with a diverse range of choices for precise aneurysm embolization.

About MicroPort® NeuroTech

Founded in Shanghai in 2012, MicroPort® NeuroTech Limited (“MicroPort® NeuroTech”), an associated company of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment. Currently, our solutions support 100+ cerebrovascular stenting procedures every day. In the future, MicroPort® NeuroTech will invest more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro intervention solutions for doctors and patients.

More information is available at www.medneurotech.com.


  1. Data on file.